

AUGUST 2017 PBAC MEETING – OTHER MATTERS

DRUG, SPONSOR, TYPE OF SUBMISSION	DRUG TYPE OR USE	LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION	PBAC OUTCOME
<p>Australian Rheumatology Association (ARA):</p> <p>Requests from ARA</p>	<p>Various</p>	<p>Various requests around prescribing PBS subsidised biological medicines</p>	<p>The PBAC did not recommend removing the criteria of allowing patients to fail or cease to achieve a response to three biological medicines, and the requirement of a five year break in biological therapy if a patient fails or ceases to respond to three biological medicines for those indications where these criteria apply. The PBAC considered that removal of these criteria may result in continuous cycling of biological medicines, which would in turn likely affect the cost-effectiveness and utilisation of these medicines.</p>